Thermo Fisher Scientific has unveiled the One Lambda™ HybriType™ HLA Plus Typing Flex kit, a cutting-edge next-generation sequencing (NGS) solution designed to enhance human leukocyte antigen (HLA) typing research. Leveraging a novel hybrid capture assay with a probe-based design, the kit ensures optimized read balance and minimizes allele dropout, promoting high-confidence genotyping results.

Targeting the needs of HLA scientists and immunogenetics researchers, the HybriType assay supports comprehensive Class I (4-field) and Class II (3-field) genotyping with robust flexibility. Compatible with diverse sample types—including whole blood and buccal swabs—the platform delivers ≥99.8% concordance, thanks to extensive gene coverage and a streamlined workflow.

With a universal protocol that reduces time-to-results to under 5.5 hours, and less than 2.5 hours of hands-on time, researchers benefit from an efficient and scalable solution. Integration with TypeStream™ Visual NGS Software further accelerates analysis through powerful automation.

Key Features of the One Lambda™ HybriType™ HLA Plus Typing Flex Kit

• Probe-Based NGS Assay: Improves read uniformity and reduces allele dropout.

• Flexible Genotyping: Covers HLA Class I and II loci, plus optional MHC and ABO loci.

• Fast Turnaround: Sample to sequencing in under 5.5 hours.

• Broad Compatibility: Works with whole blood and buccal swabs.

• Automated Analysis: Includes TypeStream™ Visual NGS Software for streamlined workflows.